7:30 am Coffee Room Opens
8:20 am Chair’s Opening Remarks
8:30 am Low HER2 Breast Cancer: Definition & Future Plans for Management
Synopsis
• Navigating clinical development for the treatment of patients with HER2-expressing solid tumors, including HER2-low tumors
• Delving into latest results and future directions
Developing a Clinically Successful HER2 ‘Low’ Agent
9:00 am Exploring Cell Therapies in HER2 Solid Tumors
Synopsis
• Discussing target engagement and response biomarkers
• Targeting tumors, targeted therapies & more
• Exploring T cell Antigen Coupler (TAC) technology
9:30 am Tumor-Localized Co-Stimulatory T-Cell Engagement by the 4-1BB/ HER2 Bispecific
Synopsis
• Exploring the drug discovery process: target identification and validation, antitumor effect, pathway understanding, biomarkers
• Discussing potential indications
• Forecasting the future to be monotherapy and/or combination dominated
• Discussing the biomarker and patient status
• Latest data and future directions
10:00 am Trends for ERBB2 and Her2-Targeting Therapies in Real-World Multi-Modal Data
Synopsis
- The Tempus platform supports assessment of tumor genetics, transcriptomics, imaging and clinical outcomes across our vast US clinical network
- Integration of multiple data modalities enables integration of Her2 status in the context of most other clinical biomarkers relevant to breast cancer
- Transcriptomics can provide a surrogate to expand the clinical utility of Her2 outside of indications tested with IHC/FISH
10:30 am Morning Refreshments
Overcoming Resistance Mechanisms & Addressing Metastatic Disease with Novel Applications
11:00 am AMX-818: A Next Generation Conditionally Active, Masked T-Cell Engager for the Treatment of HER2-Expressing Solid Tumors.
Synopsis
• Exploring the drug discovery process: target identification and validation, antitumor effect, pathway understanding, biomarkers
• Discussing potential indications
• Forecasting monotherapy and/or combination dominated
• Latest data and future directions
11:30 am Novel Immunotoxin MT-5111 in Avoiding Competition With & Overcoming the Primary Mechanisms of Tumor Resistance to Current HER2-Targeted Therapies
Synopsis
• Exploring the drug discovery process: target identification and validation, antitumor effect, pathway understanding, biomarkers
• Discussing potential indications
• Discussing the biomarker and patient status
• Latest data and future directions
12:00 pm Resistance to Immunotherapy Caused by MUC4 Expression in HER2+ Tumors – Bench to Bedside
Synopsis
• Exploring how MUC4 expression predicts resistance to immunotherapy
• Targeting soluble TNF reverses resistance in animal models
• Understand how knowing the MUC4 status of a patient’s tumor will improve clinical decision making and should benefit patient outcome
12:30 pm Zenocutuzumab, a HER2×HER3 Biclonics® Antibody that can Overcome HER3 Mediated NRG1 Signaling in Tumor Cells by Docking on HER2
Synopsis
• Understanding the status of HER2 and NRG1 fusions
• Understanding how Merus are overcoming resistance & leveraging inhibition of signaling
• Uncovering the latest data and future directions
1:00 pm Lunch Break
Patient Selection & Management for HER2-Targeted Therapies
2:00 pm Delving into Patient Selection for HER2 Targeted Basket Trials
Synopsis
• Unique challenges in patient selection
• Lessons learned
2:30 pm Management of Patients Treated with HER2 Targeted Therapies: What to Expect & What to Protect
Synopsis
• Major safety concerns of HER2 targeted therapies
• Management of toxicities
• Risks & strategy for potential combinations
3:00 pm Afternoon Refreshments
3:30 pm Closing Roundtable Session: Future Directions & Implementations for Our Anti-HER2 Drug Development Efforts’
Synopsis
- Tables thoughts and rationale on potential best combinations for own HER2 agents
- Tables thoughts on biosimilars
- Peers thoughts on understanding the effects and pathology on downstream signaling when resistance arises
- Peers thoughts on the movement towards considering the entire patient journey in treatment & regulatory input
- Are HER2 antagonists interesting to the table?
- Thoughts on dealing with the lack of homogeneity – future directions and how to advance this space
- Peers views on designing for approval in monotherapy vs combination therapy
- Opinions on how to best take novel targets into the clinic
- Tables thoughts on disease selection & challenges that come with it
- Opinions on where is this field going?